La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Adicet Bio a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Adicet Bio..

Adicet Bio (NASDAQ:ACET) Azioni, Catena delle Opzioni

Adicet Bio

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Adicet Bio Inc

First gamma delta CAR T cell therapy with the potential to address solid tumors entering clinical trials
Preliminary Phase 1 clinical data expected in the first half of 2025
Adicet Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC).

Biotech

News

General

ACET

Adicet Opens Enrollment For ADI-270 Phase 1 Clinical Trial In Metastatic/Advanced Clear Cell Renal Cell Carcinoma; First Gamma Delta CAR T Cell Therapy With The Potential To Address Solid Tumors Entering Clinical Trials; Preliminary Phase 1 Clinical Data Expected In The First Half Of 2025

HC Wainwright &amp; Co. analyst Edward White reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Neutral.

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Neutral on Adicet Bio

-Data demonstrate characteristics essential for treatment of autoimmune diseases, including robust tissue homing and complete CD19+ B cell depletion in secondary lymphoid tissue
-Results highlight the potential benefits unique to gamma delta 1 CAR T cell therapy and ADI-001's potential as a best-in-class off-the-shelf cell therapy for autoimmune diseases
-The company is pursuing ADI-001 in a basket study across six indications including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV)

Reported Saturday, Adicet Bio Shared Clinical Biomarker Data On Off-The-Shelf CAR T Cell Therapy During Oral Session At ACR Convergence 2024

Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.35) by 2.86 percent. This is a 52.11 percent increase over losses of $(0.71) per share from the same period last year.

Earnings

Earnings Beats

Adicet Bio Q3 EPS $(0.34) Beats $(0.35) Estimate

WIIM

Adicet Bio shares are trading higher after the company announced FDA clearance of an IND amendment to evaluate ADI-001 in idiopathic inflammatory myopathy and stiff person syndrome.

Adicet Bio Announces FDA Clearance Of An IND Amendment To Evaluate ADI-001 In Idiopathic Inflammatory Myopathy And Stiff Person Syndrome

Wedbush analyst Robert Driscoll reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Outperform and maintains $5 price target.

Price Target

Wedbush Reiterates Outperform on Adicet Bio, Maintains $5 Price Target

ADI-001 demonstrated robust tissue trafficking resulting in high levels of ADI-001, significant chimeric antigen receptor (CAR) T cell activation, and complete CD19+ B cell depletion in secondary lymphoid tissue.&nbsp;

Health Care

Adicet Bio Announced ADI-001 Clinical Biomarker Data From The Phase 1 GLEAN Trial Which Further Reinforces The Potential Of ADI-001 As Allogeneic Cell Therapy For Autoimmune Diseases

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58a5e02a43eaaa00018d939e/edward-white">HC Wainwright &amp; Co. analyst Edward White</a> downgraded the rating for Adicet Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) from Buy to Neutral. Adicet Bio shares fell 3.4% to close at $1.43 on Tuesday. <a href="https://www.benzinga.com/quote/DACETPZ/analyst-ratings">See how other analysts </a><a href="https://www.benzinga.com/quote/ACET/analyst-ratings">view </a><a href="https://www.benzinga.com/quote/DACETPZ/analyst-ratings">this stock</a>.</li>
<li>B of A Securities analyst Graham Perry downgraded Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) from Buy to Neutral and lowered the price target from $135 to $130. Novartis shares fell 0.2% to close at $116.99 on Tuesday. <a href="https://www.benzinga.com/quote/NVS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/topic/david-amsellem">Piper Sandler analyst David Amsellem</a> downgraded the rating for Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) from Overweight to Neutral and cut the price target from $41 to $36. Supernus Pharmaceuticals shares fell 1.2% to close at $33.49 on Tuesday. <a href="https://www.benzinga.com/quote/SUPN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Gregory Fraser downgraded ANI Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) from Buy to Hold and slashed the price target from $80 to $60. ANI Pharmaceuticals shares fell 5.1% to close at $55.48 on Tuesday. <a href="https://www.benzinga.com/quote/ANIP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NVS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="537" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88-1024x537.png" alt="" class="wp-image-542353" style="width:625px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88-1024x537.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88-768x402.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88.png 1292w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:<a href="https://www.benzinga.com/news/24/09/40792510/jim-cramer-says-aes-is-very-inexpensive-recommends-buying-this-industrial-stock"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40792510/jim-cramer-says-aes-is-very-inexpensive-recommends-buying-this-industrial-stock">Jim Cramer Says AES Is &#8216;Very Inexpensive&#8217;, Recommends Buying This Industrial Stock</a></li>
</ul>

Downgrades

Markets

Trading Ideas

ANIP

RLAY

SUPN

This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday

Jones Trading analyst Soumit Roy maintains Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Buy and lowers the price target from $6 to $4.

Jones Trading Maintains Buy on Adicet Bio, Lowers Price Target to $4

Canaccord Genuity analyst John Newman maintains Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Buy and lowers the price target from $19 to $8.

Canaccord Genuity Maintains Buy on Adicet Bio, Lowers Price Target to $8

HC Wainwright &amp; Co. analyst Edward White downgrades Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) from Buy to Neutral.

HC Wainwright & Co. Downgrades Adicet Bio to Neutral

On September 10, 2024, Adicet Bio, Inc. (the Company or Adicet) announced a strategic prioritization to focus ADI-001 development resources on autoimmune indications. The Company is focusing on advancing the clinical development of ADI-001 in four autoimmune indications, which include lupus nephritis, systemic lupus erythematosus, systemic sclerosis and anti-neutrophil cytoplasmic autoantibody associated vasculitis, and expects to further expand ADI-001 clinical development into additional autoimmune indications in the near term. Due to this prioritization, patient enrollment in the Phase 1 clinical study of ADI-001 in mantle cell lymphoma (MCL) has been closed, and topline results are reported below.
Across all doses, 10 evaluable patients with MCL that were treated with ADI-001 demonstrated an overall response rate (ORR) of 80% (8/10), a complete response (CR) rate of 60% (6/10), with a median duration of complete response of 17.5 months as of August 22, 2024. Patients were heavily pretreated with a median of 3 prior lines of therapy and 30% of patients had progressed on prior CAR T. In the Phase 1 study, ADI-001 demonstrated a favorable safety and tolerability profile, with no occurrences of graft-versus-host disease and low incidence of grade ≥3 cytokine release syndrome and neurotoxicity that compared favorably to data reported for autologous CD19 CAR T in MCL. Additional translational data from patients enrolled in the Phase 1 clinical study in relapsed/refractory B-cell non-Hodgkin's Lymphoma, which further support the significant potential of ADI-001 in autoimmune indications, will be presented during the 9th Annual CAR-TCR Summit on September 19, 2024 in Boston, MA.

Adicet Bio Shifts Focus to Autoimmune Diseases, Closes Lymphoma Trial for ADI-001

HC Wainwright &amp; Co. analyst Edward White reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Buy and maintains $10 price target.

HC Wainwright & Co. Reiterates Buy on Adicet Bio, Maintains $10 Price Target

Canaccord Genuity analyst John Newman maintains Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) with a Buy and maintains $19 price target.

Canaccord Genuity Maintains Buy on Adicet Bio, Maintains $19 Price Target

Adicet Bio Q2 2024 GAAP EPS $(0.33) Beats $(0.36) Estimate, Cash And Cash Equivalents Were $224.1M Will Be Sufficient To Fund Its Operating Expenses Into The Second Half Of 2026

H.C. Wainwright analyst Edward White reiterated a Hold rating on Adicet Bio (ACET – Research Report) today. The company's shares closed last Friday...

H.C. Wainwright Remains a Hold on Adicet Bio (ACET)

Adicet Bio ( ($ACET) ) has provided an update. Adicet Bio has received FDA clearance to expand its investigational new drug application, allowing t...

Adicet Bio Advances FDA-Approved Autoimmune Therapy Trials

In a report released today, Edward White from H.C. Wainwright reiterated a Hold rating on Adicet Bio (ACET – Research Report). The company's shares...

H.C. Wainwright Reaffirms Their Hold Rating on Adicet Bio (ACET)

Adicet Bio gets FDA clearance of IND amendment for stiff person syndrome treatment

Adicet Bio GAAP EPS of -$0.34 in-line

JMP Securities analyst Reni Benjamin has maintained their neutral stance on ACET stock, giving a Hold rating today. Reni Benjamin has given his Hol...

Adicet Bio: Hold Rating Amid Financial Stability and Anticipated Clinical Data

Adicet Bio (ACET) announced that the first LN patient has been dosed in the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases. "Dosi...

Adicet Bio:1st patient dosed in trial evaluating ADI-001 in autoimmune diseases

An update from Adicet Bio ( ($ACET) ) is now available. Adicet Bio, Inc. has launched a Phase 1 clinical trial for ADI-270, targeting metastatic cl...

Adicet Bio Advances Cancer and Autoimmune Trials

The company states: "Adicet Bio (ACET) announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metas...

Adicet Bio opens enrollment for ADI-270 phase 1 clinical trial in ccRCC

Adicet Bio Inc ( ($ACET) ) has released its Q3 earnings. Here is a breakdown of the information Adicet Bio Inc presented to its investors. Adicet B...

Adicet Bio Reports Q3 2024 Results and Clinical Progress

Press Releases

Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet Bio to Participate in Upcoming Investor Conferences

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Comments

Adicet Bio

Adicet Bio (ACET) Opzioni

Adicet Bio (NASDAQ:ACET) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO